Chris Marsh, our CEO, appeared on a panel today at the CFO seminar series for the Oregon Biosciences Association. The purpose was to share learning on how to create a successful path for Mergers and Acquisition. Essentially, Chris's message was to "start with the end in mind". The focus is to build strong value for the company through the product (and protected IP), market and organizational leadership. In sum, "good companies are bought, not sold" said Chris. In addtion to Chris, the panel included Michael Phillipps, Raymond Cheung and Daniel O'Leary.

I am excited. The April edition of Chiropractor Economics is running an article on "Breath testing comes of age: Aldehydes are a vital biomarker in understanding a patient's general health from a biochemical perspective". This was coauthored by Dr. Bhairavi Parikh and Dr. Dan Murphy. The article is strong support for the role of using the breath to diagnose aldehydes and then oxidative stress. The article begins with the history of breath diagnostics and then elaborates upon the role of aldehydes and the importance of their measurement. 

Here is a link to it:

http://www.chiroeco.com/news/chiropractic-news.php?id=11107§ion=173

This blog is our forum for many things surrounding the world of Revelar.  It provides us an opportunity to share insights into free radical damage, what’s causing it, its measurement through aldehydes and ways that it can be reduced. It will also be our way to share exciting news here at Pulse Health related to Revelar. You will see posts from any number of us here. As CMO, I invite you to share your thoughts on Revelar and join our growing community.

One thing to note is the terms we can use interchangeably. While Aldehydes is consistent as the marker for measurement, what it measures has several different terms. The most common is free radical damage but you will also see the terms oxidative stress, cell damage or tissue damage used. For more details check out our science section.